Intercept Pharmaceuticals Inc (ICPT) 280.45

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Intercept Pharmaceuticals Inc (ICPT) 280.45 $ICPT

Trade-Ideas: Intercept Pharmaceuticals (ICPT) Is Today's Strong On High Relative Volume Stock
at The Street - Fri Apr 17, 9:10AM CDT
Trade-Ideas LLC identified Intercept Pharmaceuticals (ICPT) as a strong on high relative volume candidate
ICPT: 280.45 (-8.26)

Intercept Announces New Data in PBC and NASH to be Presented at EASL 2015
GlobeNewswire - Mon Apr 13, 5:01AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat neglected chronic liver diseases, announced today that several abstracts evaluating obeticholic acid (OCA) in patients with primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH) will be presented at the International Liver Congress 2015, the 50th Annual Meeting of the European Association for the Study of the Liver (EASL), being held in Vienna, Austria, from April 22-26, 2015. Intercept also announced abstracts relating to PBC to be presented by the Global PBC Study Group and the UK-PBC Group at EASL.
ICPT: 280.45 (-8.26)

Critical Alerts For Mobileye NV, Las Vegas Sands, Intercept Pharmaceuticals, AT&T and Zoe's Kitchen Released By InvestorsObserver
PR Newswire - Fri Apr 10, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for MBLY, LVS, ICPT, T and ZOES.
ZOES: 33.10 (-0.68), T: 32.86 (+0.20), ICPT: 280.45 (-8.26), LVS: 56.39 (+0.95), MBLY: 47.47 (+0.93)

Why Intercept Pharmaceuticals Inc. Exploded Higher in March
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 08, 8:04AM CDT
What: Shares of Intercept Pharmaceuticals , a clinical-stage biopharmaceutical company focused on developing novel drugs to treat chronic liver and intestinal diseases, exploded higher by 27% in March, according to data from S&P Capital IQ ,...
ICPT: 280.45 (-8.26)

Regulus Soars As AstraZeneca Grabs NASH Drug Rights
at Investor's Business Daily - Tue Apr 07, 6:41PM CDT
Regulus Therapeutics (RGLS) stock leapt Tuesday night as AstraZeneca (AZN) took its NASH fatty liver disease candidate for testing as part of their microRNA alliance. They join a crowded field of drugmakers developing treatments and making...
GILD: 104.18 (-1.02), CNAT: 6.31 (-0.15), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), ICPT: 280.45 (-8.26), ABBV: 64.52 (+0.91), RGLS: 17.40 (-0.22)

Genfit: Refuting Bearish Arguments About Genfit's Results
Logribel Biostocks - at Seeking Alpha - Mon Apr 06, 5:58PM CDT

ICPT: 280.45 (-8.26)

Intercept Pharma completes equity offering
Seeking Alpha - at Seeking Alpha - Mon Apr 06, 4:20PM CDT

ICPT: 280.45 (-8.26)

Intercept Pharmaceuticals Announces Completion of Public Offering
GlobeNewswire - Mon Apr 06, 3:10PM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat neglected chronic liver diseases, today announced the completion of its previously announced underwritten public offering of 1,200,000 shares of its common stock. In addition, Intercept today announced the completion of the sale of an additional 130,865 shares of its common stock pursuant to the partial exercise of the underwriters' option to purchase additional shares.
ICPT: 280.45 (-8.26)

Nonalcoholic Steatohepatitis Treatment Landscape Discussed in New FirstWord Research Report Published at MarketPublishers.com
PRWeb - Thu Apr 02, 12:02PM CDT
The treatment of nonalcoholic steatohepatitis (NASH) is expected to witness drastic changes in the years to come; a slew of novel therapies are competing with one another to become the first approved therapy option for NASH.
ICPT: 280.45 (-8.26), TBRA: ()

Insider Trading Alert - ICPT, WMB And FII Traded By Insiders
at The Street - Thu Apr 02, 11:19AM CDT
Stocks with insider trader activity include ICPT, WMB and FII
FII: 34.50 (+0.44), ICPT: 280.45 (-8.26), WMB: 52.56 (+1.01)

Genfit Is An Even Bet To Recover In The NASH Race
Clinically Sound Investor - at Seeking Alpha - Tue Mar 31, 3:43PM CDT

RPTP: 10.56 (-0.17), GILD: 104.18 (-1.02), CNAT: 6.31 (-0.15), ICPT: 280.45 (-8.26)

Healthcare Hedge Fund Orbimed's Top Picks And New Move
Insider Monkey - Seeking Alpha - Tue Mar 31, 10:37AM CDT
By Usman Rafi According to a Schedule 13D Form filed yesterday with the Securities and Exchange Commission, Samuel Islay's Orbimed Advisors has slashed its stake in Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT ) by about 14%. The fund...
BIIB: 423.57 (+1.46), ICPT: 280.45 (-8.26), AMGN: 169.10 (+0.64), BMY: 66.60 (-0.21)

InsiderInsights.com Daily Round Up 3/30/15: VEEV, VNCE, PRSS, OGS
InsiderInsights - at Seeking Alpha - Tue Mar 31, 9:55AM CDT

GIII: 116.32 (-1.15), KIRK: 23.48 (+0.13), LNG: 78.61 (+1.61), VNCE: 19.10 (-0.08), UE: 23.57 (-0.02), AET: 107.95 (-0.41), VEEV: 27.12 (+0.28), PRSS: 3.80 (-0.11), WIW: 11.45 (unch), DVA: 83.22 (+0.10), PRE: 129.50 (-0.21), ARMK: 31.30 (+0.32), CPF: 23.52 (+0.35), FSB: 20.42 (-0.53), PHII: 31.78 (+0.40), RIT: 12.95 (-0.01), ICPT: 280.45 (-8.26), OGS: 42.39 (-0.28), ALCO: 48.09 (-1.52), WIA: 11.60 (-0.04)

Genfit: Misunderstandings And Propaganda About Phase 2b Results Provide A Good Entry Point
Logribel Biostocks - at Seeking Alpha - Tue Mar 31, 9:10AM CDT

ICPT: 280.45 (-8.26)

Intercept Pharma prices equity offering
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 8:22AM CDT

ICPT: 280.45 (-8.26)

Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Tue Mar 31, 8:13AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat neglected chronic liver diseases, today announced the pricing of an underwritten public offering of 1,200,000 shares of its common stock. The underwriters intend to offer the shares of common stock from time to time for sale in one or more transactions on The Nasdaq Global Select Market, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. Intercept granted the underwriters 30-day option to purchase up to an additional 180,000 shares of common stock, on the same terms and conditions.
ICPT: 280.45 (-8.26)

Genfit's French Fans Fume Following Failure of Fatty Liver Drug
at The Street - Tue Mar 31, 7:51AM CDT
French investors holding shares of Genfit are having trouble coping with the failure of the company's fatty liver disease drug GFT505.
ICPT: 280.45 (-8.26), TWTR: 51.73 (+0.41)

Intercept Pharma initiates equity offering
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 6:06AM CDT

ICPT: 280.45 (-8.26)

Intercept Pharmaceuticals Announces Proposed Offering of Common Stock
GlobeNewswire - Tue Mar 31, 5:24AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat neglected chronic liver diseases, today announced that it is commencing an underwritten public offering of 1,200,000 shares of its common stock. All of the shares in the offering are to be sold by Intercept. The underwriters intend to offer the shares of common stock from time to time for sale in one or more transactions on The Nasdaq Global Select Market, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. Intercept intends to grant the underwriters a 30-day option to purchase up to an additional 180,000 shares of common stock, on the same terms and conditions.
ICPT: 280.45 (-8.26)

Nasdaq stocks posting largest percentage increases
AP - Fri Mar 27, 5:10PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
SAGE: 59.50 (-2.56), NAME: 9.57 (-0.16), DERM: 15.36 (-0.62), ORMP: 7.25 (-0.10), CNAT: 6.31 (-0.15), ALTR: 42.78 (-0.46), ICPT: 280.45 (-8.26), FIVE: 35.27 (-0.01), ROLL: 75.54 (+0.32)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aimbient's OR Timestamp Study Puts Efficiency to Test

Updated Category News Views 160

A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...

Continue Reading
Linq's $90M Bet on the Infrastructure Behind AI Agents

Updated Category News Views 193

Ninety million dollars just landed on the least glamorous part of the AI-agent rush: the pipes. Linq, the San Francisco private company, announced the round on November 18, 2026, led by Andreessen Horowitz, with returning backing from TQ Ventures, Mucker Capital and Abstract, plus new money from Anthos and Left Lane Capital. Ben Horowitz is joining the board. That is a...

Continue Reading
Mudrick Urges Doncasters to Test a Strategic Sale Now

Updated Category News Views 0

Castings are rarely glamorous until nobody can get them, and Mudrick Capital is betting that ugly little industrial reality could make Doncasters worth far more in a takeover than the market currently credits. The event-driven investor, which says it owns roughly 4.3% of DPC Holdings Limited, has asked the board to quietly evaluate strategic alternatives, including a sale...

Continue Reading
1095 Days Finds the Army's Long, Ordinary War Life

Updated Category News Views 125

A cracked barracks window can explain more than a polished battlefield legend. Dean R. Cherry's 1095 Days: Three Years in the Green Machine, newly released by Palmetto Publishing, puts its weight on the parts of Army life that war stories often shove into the background: cold, waiting, paperwork, arbitrary rules, lousy living conditions, and the private mental math of...

Continue Reading
Insta360 Tests Holiday Demand With $170 Gear Discounts

Updated Category News Views 102

A discount banner can reveal plenty about a hardware brand's priorities, and Insta360's latest Black Friday push is plainly built to put more of its ecosystem into customers' hands. The company is advertising savings of up to US$170 across cameras, gimbals, microphones, webcams, and accessories, with the promotion available for a limited time through its own store and...

Continue Reading
Health In Tech Gets a Real Distribution Test in 2027

Updated Category News Views 67

A 100,000-employee funnel is the sort of number that makes a small InsurTech investor sit up, then reach for the fine print. Health In Tech has brought a national third-party administrator onto its eDIYBS platform, giving the company access to a TPA serving more than 650 employers in over 40 states, with more than 100,000 covered employees as of May 2026. That is...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 48

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
FAMID's Six-Month IVDR Win Opens Europe's Market Door

Updated Category News Views 55

A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....

Continue Reading
Teachers in Space Takes Its Classroom Model Orbital

Updated Category News Views 131

Two teachers strapped into a research flight may sound like a glossy space-age photo op, but the useful part of this plan sits back in the classroom with the students staring at the data. Teachers in Space wants to send two educators aboard a Virgin Galactic research flight expected in 2027, and it is raising $2 million to fund the broader educational program and mission....

Continue Reading
Roof Leaks Demand Diagnosis Before the Repair Bill

Updated Category News Views 95

A brown ring on a ceiling is often the last witness, not the crime scene. That is the useful, unglamorous point in Jonathan Floyd's HelloNation discussion of roof leaks: water has plenty of ways to move after it slips past a roof's defenses. Homeowners understandably stare at the stain and assume the answer sits directly overhead. Sometimes it does. Plenty of times, it...

Continue Reading

Top 5 Most Recently Viewed Articles

BioMarin's Strong 2024 Performance Fuels 2025 Expectations

Updated Category News Views 392

BioMarin's Empowering Growth Journey Into 2025 BioMarin Pharmaceutical Inc. has marked a significant achievement with its record performance in 2024, setting a strong foundation for the upcoming year. The company demonstrated robust operational execution and is gearing up for a year of potential double-digit revenue growth as it advances its corporate strategy focusing on...

Continue Reading
Berkshire Hills Bancorp Declares Cash Dividend for Shareholders

Updated Category News Views 104

Berkshire Hills Bancorp Announces Quarterly Dividend Berkshire Hills Bancorp, Inc. (NYSE: BHLB) has recently declared a quarterly cash dividend of $0.18 per common share for its shareholders. This decision by the Board of Directors aims to reward shareholders who are on record by a specified date. Details of the Dividend Announcement The approved cash dividend will be...

Continue Reading
Maiden United Transforms Adele's Skyfall into Heavy Metal Epic

Updated Category News Views 167

Maiden United Transforms Iconic Adele Song into Heavy Metal What if Iron Maiden had recorded the legendary James Bond theme song? Maiden United, a notable tribute band dedicated to Iron Maiden, has taken that intriguing concept and turned it into reality. The band has just unveiled their latest EP entitled Agent 666, which features an electrifying heavy metal cover of...

Continue Reading
Cherokee Federal Boosts Growth with MSI, LLC Investment

Updated Category News Views 213

Cherokee Federal Expands Presence Through Strategic Investment Cherokee Federal, a division of Cherokee Nation Businesses (CNB), has recently announced a significant move in the federal contracting realm. They have acquired a majority stake in Management Science and Innovation, LLC, also known as MSI. This strategic investment marks another milestone under their...

Continue Reading
Metallurgical Coal Market Expected Growth Amid Steel Demand Spike

Updated Category News Views 125

Growth of the Metallurgical Coal Market The global metallurgical coal market is poised for significant growth, estimated at USD 95.27 billion from 2024 to 2028. This growth is largely driven by the increasing demand for steel, which is essential for numerous infrastructure projects around the world. As smart city developments surge, the necessity for high-quality steel...

Continue Reading